Amarin (AMRN) Volatility Nearly Double into PDUFA for AMR101

Article Stock Quotes (1) Comments (0)

Amarin Corp. (Nasdaq: AMRN) volatility is slightly elevated on the session, but at 9 percent is nearly double the trailing annual average, heading into the pharma's PDUFA date tomorrow (July 26th) for AMR101.

Today, Amarin received notice of intention to grant letter for European Patent Application Number EP2395991, titled "Use of Eicosapentaenoic Acid Ethyl Ester for Treating Hypertriglyceridemia."

Amarin noted that this patent application "is intended to protect the exclusivity of Amarin's drug candidate, AMR101, for use in an indication that Amarin may seek through the European Medicines Agency (EMA)."

Shares of Amarin hit a new 52-week high last Thursday, and have held above at the upper-quarter of $14 or above since.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Amarin (AMRN) NCE Delay Not all Negative - MKM Partners
• Amarin (AMRN) Vascepa NCE Not in Latest FDA Orange Book Update
• Tesla (TSLA) Ramps Higher (GM)

Create E-mail Alert Related Categories

FDA, Insiders' Blog, Options

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?